Traws Pharma Inc (TRAW)

$1.34 -0.08 (-5.63%)
Market Cap 8.40M
Revenue (ttm) 230,000.00
Net Income (ttm) -166.52M
EPS (ttm) N/A
PE Ratio 0.02
Forward PE N/A
Profit Margin -72,400.00%
Debt to Equity Ratio 0.00
Volume 145,600
Avg Vol 143,612
Day's Range N/A - N/A
Shares Out 5.56M
Stochastic %K 2%
Beta 1.14
Analysts Strong Buy
Price Target $6.00

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3680
Fax: 267 759 3681
Address:
12 Penns Trail, Newtown, United States
Pharma_Stock_Calls
Pharma_Stock_Calls Aug. 19 at 10:41 PM
🚨 New Signal ✅ 💊 $TRAW 🗓️ Aug 19, 2025 🎯 Entry: $1.3400 🎯 Target: $1.5998 (+19.39%)
1 · Reply
JohnSmith1212
JohnSmith1212 Aug. 19 at 2:00 PM
$TRAW
0 · Reply
Twitties00
Twitties00 Aug. 19 at 12:16 PM
$TRAW
0 · Reply
Rafiullah_100
Rafiullah_100 Aug. 19 at 4:43 AM
$TRAW nice volume still downgrade.
0 · Reply
Twitties00
Twitties00 Aug. 18 at 11:08 PM
$TRAW Please give me strength to deal with this downturn 🙏
0 · Reply
aaron03
aaron03 Aug. 18 at 8:42 PM
$TRAW @Twitties00 You're awfully quiet today
1 · Reply
JohnSmith1212
JohnSmith1212 Aug. 18 at 3:24 PM
$TRAW
0 · Reply
Schube1255
Schube1255 Aug. 18 at 3:20 PM
$PANW $TRAW
0 · Reply
papaCGC
papaCGC Aug. 18 at 2:11 PM
$TRAW got out on the pop this morning, waiting on re entry
0 · Reply
Jbjb90
Jbjb90 Aug. 18 at 11:37 AM
$TRAW https://www.stocktitan.net/news/TRAW/traws-pharma-receives-approval-to-proceed-with-phase-2-covid-studies-8xvwn316y4c5.html
0 · Reply
Latest News on TRAW
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 1 day ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 1:14 PM EDT - 5 days ago

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 14, 2025, 7:00 AM EDT - 5 days ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Aug 8, 2025, 7:00 AM EDT - 11 days ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 30, 2025, 6:30 AM EDT - 7 weeks ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025, 8:00 AM EDT - 3 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 3 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Apr 1, 2025, 8:50 PM EDT - 4 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 5 months ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 5 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 5 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 5 months ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 6 months ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 6 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 7 months ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 7 months ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 8 months ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 8 months ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 8 months ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 9 months ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 11 months ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 11 months ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 11 months ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 1 year ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 1 year ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 8:18 PM EST - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 1 year ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Onconova Expands Leadership Team with Two Key Appointments

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

May 4, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Apr 6, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Mar 16, 2023, 9:56 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Pharma_Stock_Calls
Pharma_Stock_Calls Aug. 19 at 10:41 PM
🚨 New Signal ✅ 💊 $TRAW 🗓️ Aug 19, 2025 🎯 Entry: $1.3400 🎯 Target: $1.5998 (+19.39%)
1 · Reply
JohnSmith1212
JohnSmith1212 Aug. 19 at 2:00 PM
$TRAW
0 · Reply
Twitties00
Twitties00 Aug. 19 at 12:16 PM
$TRAW
0 · Reply
Rafiullah_100
Rafiullah_100 Aug. 19 at 4:43 AM
$TRAW nice volume still downgrade.
0 · Reply
Twitties00
Twitties00 Aug. 18 at 11:08 PM
$TRAW Please give me strength to deal with this downturn 🙏
0 · Reply
aaron03
aaron03 Aug. 18 at 8:42 PM
$TRAW @Twitties00 You're awfully quiet today
1 · Reply
JohnSmith1212
JohnSmith1212 Aug. 18 at 3:24 PM
$TRAW
0 · Reply
Schube1255
Schube1255 Aug. 18 at 3:20 PM
$PANW $TRAW
0 · Reply
papaCGC
papaCGC Aug. 18 at 2:11 PM
$TRAW got out on the pop this morning, waiting on re entry
0 · Reply
Jbjb90
Jbjb90 Aug. 18 at 11:37 AM
$TRAW https://www.stocktitan.net/news/TRAW/traws-pharma-receives-approval-to-proceed-with-phase-2-covid-studies-8xvwn316y4c5.html
0 · Reply
Twitties00
Twitties00 Aug. 18 at 11:34 AM
$TRAW just going to say this again. The potential annual market for each of the two antivirals is BILLIONS. The potential for stockpiling is BILLIONS. The potential if Bird Flu accelerates is BILLIONS. 🇺🇸💎🔥⏱️
0 · Reply
Twitties00
Twitties00 Aug. 18 at 11:27 AM
$TRAW need to get some new links 😎
0 · Reply
sthm
sthm Aug. 18 at 11:02 AM
$TRAW Traws Pharma Receives Approval to Proceed With Phase 2 Covid Studies With Ratutrelvir, Expects Results by Year-End 2025
0 · Reply
Twitties00
Twitties00 Aug. 18 at 12:43 AM
$TRAW 💎
0 · Reply
aaron03
aaron03 Aug. 17 at 11:39 PM
$TRAW I don't want to sound harsh @Twitties00, but you have over 44,000 watchers on this stock and you're the only one who posts? I mean it's trading at $1.51/share. I hope it turns around, but the previous regime was an epic failure.
1 · Reply
Twitties00
Twitties00 Aug. 17 at 11:11 PM
$SPY $TRAW
0 · Reply
Twitties00
Twitties00 Aug. 17 at 10:06 PM
$TRAW 🔥
0 · Reply
Twitties00
Twitties00 Aug. 16 at 1:00 AM
$TRAW https://fortune.com/2024/06/24/us-strategic-drug-stockpile-inadequate-bird-flu-outbreak/
1 · Reply
Twitties00
Twitties00 Aug. 15 at 7:04 PM
$TRAW 🥱😴🇺🇸⏱️💎
0 · Reply
CaptTim
CaptTim Aug. 15 at 2:01 PM
$TRAW sorry, but this is a pile of shit.
1 · Reply
Twitties00
Twitties00 Aug. 15 at 11:23 AM
$TRAW 🇺🇸💎⏱️
0 · Reply
toughguy45
toughguy45 Aug. 15 at 8:05 AM
$TRAW I be gettin those benjamins for years shorting this worthless pos
0 · Reply